[1] Kajal K, Premkumar M, Izzy M, et al. Cirrhotic cardiomyopathy influences clinical outcomes and enhances performance of conventional risk prediction models in acute-on-chronic liver failure with severe sepsis[J].Aliment Pharmacol Ther, 2023,58(9):903-919.
[2] van den Boom BP, Stamouli M, Timon J, et al. Von Willebrand factor is an independent predictor of short-term mortality in acutely ill patients with cirrhosis[J]. Liver Int, 2023,43(12): 2752-2761.
[3] Hernaez R, Karvellas CJ, Liu Y, et al. The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure[J]. J Hepatol, 2023,79(3): 717-727.
[4] Zhu B, Gao F, Li Y, et al. Serum cytokine and chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure[J].Front Immunol, 2023,14:1133656.
[5] Luo J, Liang X, Xin J, et al. Predicting the Onset of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure[J].Clin Gastroenterol Hepatol, 2023, 21(3): 681-693.
[6] Verma N, Choudhury A, Singh V, et al. APASL-ACLF Research Consortium-Artificial Intelligence (AARC-AI) model precisely predicts outcomes in acute-on-chronic liver failure patients[J]. Liver Int, 2023,43(2): 442-451.
[7] Weiss E, de la Peña-Ramirez C, Aguilar F,et al. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)[J]. Gut, 2023,72(8): 1581-1591.
[8] Zhang Y, Tan W, Wang X, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023,79(5): 1159-1171.
[9] Agarwal B, Cañizares RB, Saliba F, et al. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure[J]. J Hepatol, 2023, 79(1): 79-92.
[10] Sharma S, Agarwal S, Saraya A, et al. Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure[J]. Hepatol Int, 2023, 17(4): 989-999.
[11] He L, Cai Q, Liang X, et al. ETS2 alleviates acute-on-chronic liver failure by suppressing excessive inflammation[J].J Med Virol, 2023, 95(4): e28710.
[12] Zhang Y, Zhang X, Han J, et al. Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure[J]. Hepatol Int, 2023,17(4): 1000-1015.
[13] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023, 79(2): 461-491.
[14] Nanchal R, Subramanian R, Alhazzani W, et al. Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations[J]. Crit Care Med, 2023,51(5): 657-676.
[15] Badal BD, Cox J, Bajaj JS. Are we ready to translate metabolomics into clinical practice for ACLF prediction and diagnosis[J]? J Hepatol, 2023, 79(5):1082–1084
[16] 中国中西医结合学会,中华中医药学会,中华医学会.慢加急肝衰竭中西医结合诊疗指南[J].北京中医药,2023,42(6):596-606.
[17] Gu WY, Xu BY, Zheng X,et al. Acute-on-chronic liver failure in China: Rationale for developing a patient registry and baseline characteristics[J]. Am J Epidemiol, 2018,187(9):1829–1839
[18] Qiao L, Wang XB, Deng GH et al. Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure. (CATCH-LIFE) study[J]. BMJ Open,2021,11: e037793 |
